

Freedom of Information Act 2000**The Royal Cornwall Hospitals NHS Trust Response to Information request****Date Request Received: 12 July 2022****FOI Ref No: 17308****Requested Information**

- 1) How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:
 - Carboplatin (monotherapy or in combination with 5-FU)
 - Cisplatin (monotherapy or in combination with 5-FU)
 - Cetuximab with/without chemotherapy
 - Cetuximab with radiotherapy
 - Pembrolizumab monotherapy
 - Pembrolizumab with chemotherapy
 - Nivolumab
 - Docetaxel (monotherapy or in combination with 5-FU)
 - Fluorouracil (5FU)
 - Radiotherapy only
 - Other
- 2) For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:
 - Total number of head and neck cancer patients
 - Number of locally advanced head and neck cancer patients
 - Number of unresectable recurrent and/or metastatic head and neck cancer patients
- 3) How many Urothelial cancer patients have been treated in the past 3 months with the following agents:
 - Avelumab
 - Atezolizumab
 - Carboplatin with Gemcitabine
 - Carboplatin single or in any other combination
 - Cisplatin with Gemcitabine
 - Cisplatin single or in any other combination
 - Nivolumab
 - Pembrolizumab
 - Any other regimen including Paclitaxel
 - Any other chemotherapy regimen
 - Other active systemic anti-cancer therapy [please state]
 - Palliative care only

- 4) Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Response

- 1) How many patients have been treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the following agents:

• Carboplatin (monotherapy or in combination with 5-FU)	3
• Cisplatin (monotherapy or in combination with 5-FU)	6
• Cetuximab with/without chemotherapy	1
• Cetuximab with radiotherapy	0
• Pembrolizumab monotherapy	5
• Pembrolizumab with chemotherapy	0
• Nivolumab	4
• Docetaxel (monotherapy or in combination with 5-FU)	0
• Fluorouracil (5FU)	0
• Radiotherapy only	16
• Other	14

- 2) For the patients treated in the past 3 months for head and neck cancer (squamous cell carcinoma) with the therapies listed in the first question, please provide:

• Total number of head and neck cancer patients	19
• Number of locally advanced head and neck cancer patients	7
• Number of unresectable recurrent and/or metastatic head and neck cancer patients	12

- 3) How many Urothelial cancer patients have been treated in the past 3 months with the following agents:

• Avelumab	8
• Atezolizumab	8
• Carboplatin with Gemcitabine	7
• Carboplatin single or in any other combination	0
• Cisplatin with Gemcitabine	9
• Cisplatin single or in any other combination	0
• Nivolumab	0
• Pembrolizumab	0
• Any other regimen including Paclitaxel	0
• Any other chemotherapy regimen	1
• Other active systemic anti-cancer therapy [please state]	
• Palliative care only	0

- 4) Does your trust participate in any ongoing clinical trials for the treatment of head and neck cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

The Royal Cornwall Hospital Trust has a trial called Poppy which has 1 patient commencing treatment.

Attachment(s)

None

Date Response sent:

9th August 2022